Institute of Medical Biology, 8A Biomedical Grove, Singapore 138648.
Small G-protein Signaling and Kinases (sGSK-NRP) Group, Neuroscience Research Partnership, 61 Biopolis Drive, Singapore 138673.
J Biol Chem. 2011 Dec 2;286(48):41466-41478. doi: 10.1074/jbc.M111.283580. Epub 2011 Sep 27.
Collapsin response mediator proteins are ubiquitously expressed from multiple genes (CRMPs 1-5) and play important roles in dividing cells and during semaphorin 3A (Sema3A) signaling. Nonetheless, their mode of action remains opaque. Here we carried out in vivo and in vitro assays that demonstrate that CRMPs are a new class of microtubule-associated protein (MAP). In experiments with CRMP1 or CRMP2 and their derivatives, only the C-terminal region (residues 490-572) mediated microtubule binding. The in vivo microtubule association of CRMPs was abolished by taxol or epothilone B, which is highly unusual. CRMP2-depleted cells exhibited destabilized anaphase astral microtubules and altered spindle position. In a cell-based assay, all CRMPs stabilized interphase microtubules against nocodazole-mediated depolymerization, with CRMP1 being the most potent. Remarkably, a 82-residue C-terminal region of CRMP1 or CRMP2, unrelated to other microtubule binding motifs, is sufficient to stabilize microtubules. In cells, we demonstrate that glycogen synthase kinase-3β (GSK3β) inhibition potentiates this activity. Thus, CRMPs are a new class of MAP that binds through a unique motif, but in common with others such as Tau, is antagonized by GSK3β. This regulation is consistent with such kinases being critical for the Sema3A (collapsin) pathway. These findings have implications for cancer and neurodegeneration.
collapsin 反应介质蛋白广泛表达于多个基因(CRMPs1-5),在分裂细胞和信号转导中发挥重要作用。尽管如此,它们的作用机制仍然不清楚。我们进行了体内和体外实验,证明 CRMPs 是一类新的微管相关蛋白(MAP)。在与 CRMP1 或 CRMP2 及其衍生物的实验中,只有 C 端区域(残基 490-572)介导微管结合。紫杉醇或埃博霉素 B 可使 CRMPs 的体内微管结合作用丧失,这是非常不寻常的。CRMP2 耗竭细胞表现出不稳定的后期星体微管和改变的纺锤体位置。在基于细胞的测定中,所有 CRMPs 稳定有丝分裂期微管,使其免受诺考达唑介导的解聚作用,其中 CRMP1 作用最强。值得注意的是,CRMP1 或 CRMP2 的 82 个残基 C 端区域与其他微管结合基序无关,但足以稳定微管。在细胞中,我们证明糖原合酶激酶-3β(GSK3β)抑制可增强此活性。因此,CRMPs 是一类新的 MAP,通过独特的基序结合,但与 Tau 等其他 MAP 一样,受 GSK3β 的拮抗。这种调节与这些激酶在 Sema3A(崩溃素)途径中至关重要的作用一致。这些发现对癌症和神经退行性变具有重要意义。